Mural Oncology (MURA)
NASDAQ: MURA
· Real-Time Price · USD
2.63
0.01 (0.38%)
At close: Apr 30, 2025, 11:20 AM
0.38% (1D)
| Bid | 2.61 |
| Market Cap | 45.4M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -128.51M |
| EPS (ttm) | -7.58 |
| PE Ratio (ttm) | -0.35 |
| Forward PE | -0.79 |
| Analyst | Buy |
| Ask | 2.65 |
| Volume | 130,369 |
| Avg. Volume (20D) | 4,824,506 |
| Open | 2.60 |
| Previous Close | 2.62 |
| Day's Range | 2.59 - 2.68 |
| 52-Week Range | 0.95 - 4.74 |
| Beta | 5.32 |
About MURA
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was inco...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 16, 2023
Employees 116
Stock Exchange NASDAQ
Ticker Symbol MURA
Website https://www.muraloncology.com
Analyst Forecast
According to 4 analyst ratings, the average rating for MURA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 469.26% from the latest price.
Stock Forecasts2 weeks ago
+133.98%
Mural Oncology shares are trading higher after the...
Unlock content with
Pro Subscription
1 month ago
-61.62%
Mural Oncology shares are trading lower after the company announced it will discontinue its final analysis of Nemvaleukin in combination with KEYTRUDA and will cease further development. Jones Trading downgraded the stock from Buy to Hold.
